Geron: A biotech stock with Potential for long-term gains

21-02-2014 Seeking AlphaComments (0)

GermanyGeron Corp

Geron Corporation (GERN) may be a good investment on the basis of its patented drug candidate for myelofibrosis (MF). Myelofibrosis is a multi-billion dollar market with only a single symptomatic treatment available. In contrast, imetelstat, Geron's drug candidate for MF, has disease modifying potential. Therefore, if approved, imetelstat will be the only drug in the MF market that can modify the disease rather than treat its symptoms.


Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top